DGAP-Adhoc: Aladdin Healthcare Technologies SE reports the sale of software and intellectual property
- 38
DGAP-Ad-hoc: Aladdin Healthcare Technologies SE / Key word(s): Disposal Aladdin Healthcare Technologies SE reports the sale of software and intellectual property Aladdin Ltd has developed and is developing various AI-driven technology products for the healthcare market. It has developed prototype AI-driven Drug Discovery Platform and Knowledge Graph which can be tailored to various areas of drug development. The software being sold is the above-described intellectual property but specifically to be used for small molecule drug discovery in the area of Alzheimer's and Dementia. Aladdin retains the rights to use it in other areas. Wade Menpes-Smith Contact:
18-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Aladdin Healthcare Technologies SE |
Unter den Linden 10 | |
10117 Berlin | |
Germany | |
Phone: | 030 700140449 |
E-mail: | [email protected] |
Internet: | www.aladdinid.com |
ISIN: | DE000A12ULL2 |
WKN: | A12ULL |
Listed: | Regulated Market in Dusseldorf |
EQS News ID: | 1197804 |
End of Announcement | DGAP News Service |
|
1197804 18-May-2021 CET/CEST
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.